Author:
Wang Jiang,Zhao Liangying,Hu Xiaoshan,Lv Liting,Zhang Xiaowei,Lu Minjun,Hu Guinv
Abstract
AbstractTo explore the clinicopathological characteristics and prognostic significance of casting-type calcification (CC) in patients with breast cancer presenting with microcalcification on mammography. Data on patients with invasive breast cancer who had mammographic calcification was retrospectively analyzed. The chi-square test was utilized to assess the clinicopathological characteristics of two forms of CC-related breast cancer. The examination of prognostic variables was conducted using Kaplan–Meier and Cox regression analyses. A total of 427 eligible patients were included in this study. Chi-square analysis indicated that the presence of CC was associated with estrogen receptor (ER) negativity (P = 0.005), progesterone receptor (PR) negativity (P < 0.001), and epidermal growth factor receptor 2 (HER-2) positivity (P < 0.001); among these, the association was stronger with the CC-predominant type. After a median follow-up of 82 months, those with CC had a worse 5-year recurrence-free survival (RFS) (77.1% vs. 86.9%, p = 0.036; hazard ratio [HR], 1.86; 95% confidence interval [CI] 1.04–3.31) and overall survival (OS) (84.0% vs. 94.4%, p = 0.007; HR, 2.99; 95% CI 1.34–6.65) rates. In COX regression analysis, such differences were still observed in HER-2 positive subgroups (RFS: HR: 2.45, 95% CI 1–5.97, P = 0.049; OS: HR: 4.53, 95% CI 1.17–17.52, P = 0.029). In patients with invasive breast cancer exhibiting calcifications on mammography, the presence of CC, especially the CC-predominant type, is linked to a higher frequency of hormone receptor negativity and HER-2 positivity. The presence of CC is associated with an unfavorable 5-year RFS and OS rates.
Funder
The Science and Technology Research Program Project of Jinhua Science and Technology Bureau
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
2. Zheng, R. S. et al. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi 45, 212–220 (2023).
3. Berg, W. A. Tailored supplemental screening for breast cancer: What now and what next?. AJR Am. J. Roentgenol. 192, 390–399 (2009).
4. Venkatesan, A., Chu, P., Kerlikowske, K., Sickles, E. A. & Smith-Bindman, R. Positive predictive value of specific mammographic findings according to reader and patient variables. Radiology 250, 648–657 (2009).
5. Tabár, L. & Dean, P. B. Teaching atlas of mammography. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd 116, 1–222 (1983).